HeartBeam, Inc. (NASDAQ: BEAT) has closed an underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, was supported by key stakeholders including ClearCardio(TM), company leadership, and institutional investors.
The capital will be directed toward several strategic initiatives, primarily funding the commercialization of HeartBeam’s FDA-cleared 12-lead synthesized electrocardiogram (ECG) system. The company is also allocating resources for further development of its extended-wear patch and heart attack detection technologies, expansion of artificial intelligence capabilities, and general corporate purposes.
HeartBeam’s core technology represents a significant advancement in cardiac monitoring. The company is developing the first cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing those signals into a standard 12-lead ECG. This platform is designed for portable devices that can be used wherever a patient is located, aiming to deliver actionable cardiac intelligence outside traditional medical facilities.
The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, followed by clearance for its 12-lead ECG synthesis software in December 2025. HeartBeam holds over 20 issued patents related to its technology enablement. The company’s vision is to allow physicians to identify cardiac health trends and acute conditions remotely, potentially directing patients to appropriate care without requiring an initial facility visit.
For more detailed information, the full press release is available at https://ibn.fm/9iNYY. The latest news and updates relating to HeartBeam are available in the company’s newsroom at https://ibn.fm/BEAT.
This funding round occurs as the company advances technologies that could redefine cardiac health management by enabling comprehensive ECG monitoring outside clinical settings. The development of extended-wear patches and enhanced AI capabilities suggests a move toward continuous, rather than episodic, cardiac assessment. The financial backing from this offering provides resources to transition these cleared technologies from development to broader market availability.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is HeartBeam Secures $10 Million in Public Offering to Accelerate Cardiac Technology Deployment.